Free Trial
→ A U.S. Resource Gap Is a National Issue - and Opportunity (From i2i Marketing Group, LLC) (Ad)tc pixel
NASDAQ:RZLT

Rezolute Q3 2026 Earnings Report

Rezolute logo
$3.16 -0.14 (-4.10%)
As of 01:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Rezolute EPS Results

Actual EPS
N/A
Consensus EPS
-$0.17
Beat/Miss
N/A
One Year Ago EPS
N/A

Rezolute Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rezolute Announcement Details

Quarter
Q3 2026
Date
5/12/2026
Time
After Market Closes
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Rezolute Earnings Headlines

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society ...
May 1, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/rezolute-announces-oral-presentation-of-results-from-its-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-annual-meeting-1036095326
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
May 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/01/3286124/0/en/rezolute-announces-oral-presentation-of-results-from-its-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-annual-me.html
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
May 6 at 1:00 AM  |  Weiss Ratings (Ad)
Rezolute, Inc. Investigated by the Portnoy Law Firm
April 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/24/3280797/0/en/rezolute-inc-investigated-by-the-portnoy-law-firm.html
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
April 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/21/3277771/0/en/rezolute-to-present-results-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-pes-annual-meeting.html
Rezolute: Sell Rating Despite FDA Feedback From Type B Meeting For Ersodetug
March 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4887147-rezolute-sell-rating-despite-fda-feedback-from-type-b-meeting-for-ersodetug
See More Rezolute Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rezolute? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rezolute and other key companies, straight to your email.

About Rezolute

Rezolute (NASDAQ:RZLT), a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

View Rezolute Profile
Earnings Tools